UNSPSC 51113101: Defosfamide

This classification denotes a nitrogen mustard compound with the molecular formula C9H20Cl3N2O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0W33021S30, chemically known as phosphorodiamidic acid, n,n-bis(2-chloroethyl)-n-(3-hydroxypropyl)-, (2-chloroethyl) ester but more generally known as defosfamide, which bears US NIH Compound Identifier 71164. European Medicines Agency schedules Defosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06944MIG.

UNSPSC 51113101 Defosfamide is a Commodity code covering a chemotherapy agent — a pharmaceutical product state and local procurement offices acquire for hospital systems, correctional health services, and specialized medical facilities. State and local governments purchase defosfamide as part of broader cancer-treatment drug inventories, typically through group purchasing organizations (GPOs), prime vendors under pharmacy service contracts, or direct pharmaceutical supplier agreements. The product is a phosphoramide mustard derivative used in oncology protocols, and procurement activity reflects hospital system standardization, formulary compliance, and cost-containment decisions rather than episodic purchasing.

The source provided contains no recent state and local contract opportunities tagged to this code. Without visibility into active RFP, RFQ, IFB, or ITB records, no issuing bodies, geographic concentration, or representative solicitations can be named. Defosfamide procurement at state and local level typically flows through existing standing agreements and GPO contracts rather than open competitive solicitations, which may explain the absence of posted opportunities in the baseline record set. Business development professionals pursuing this code should monitor pharmacy benefit and hospital supply contracts at state health departments, county hospital authorities, and large municipal medical centers, and verify whether defosfamide appears in active line-item or category reviews within existing drug-supply framework agreements.